Tonix Pharm Holdings (TNXP)

$15.90 -0.25 (-1.55%)
Market Cap 139.38M
Revenue (ttm) 10.09M
Net Income (ttm) -130.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,288.80%
Debt to Equity Ratio 0.00
Volume 444,700
Avg Vol 934,888
Day's Range N/A - N/A
Shares Out 8.77M
Stochastic %K 12%
Beta 1.79
Analysts Strong Sell
Price Target $69.00

Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for...

Industry: Biotechnology
Sector: Healthcare
Phone: 862 799 8599
Fax: 862 904 8163
Address:
26 Main Street, Suite 101, Chatham, United States
ThatDudeWithNoMoney
ThatDudeWithNoMoney Nov. 17 at 4:25 AM
$TNXP To all my OG Tonix investors from 2019-2022 era. Idk if y'all are still here or lurking but it's fucking insane to have gone through all of those reverse splits and lost money to finally see TNX-102SL (Tonmya) finally hit the market. I, for one, made my losses back and made a nice profit when they announced the PDUFA news almost a year ago. Anyway, I'll be buying back in 3 months once their earnings come around. You newer investors have a nicer setup than what we had haha
1 · Reply
YourAverageStockGuy
YourAverageStockGuy Nov. 17 at 3:59 AM
$TNXP
0 · Reply
TrendSetter67
TrendSetter67 Nov. 17 at 3:06 AM
$TNXP Hey Now... the AI is channeling thoughts of a Squeeze
0 · Reply
TrendSetter67
TrendSetter67 Nov. 17 at 2:54 AM
$TNXP How did it get to #5 so quickly this evening? Driven by views rather than posts?
1 · Reply
JRoc16
JRoc16 Nov. 17 at 2:51 AM
$TNXP Tonmya Hits The Market !! Lets Freaking Go !! TRENDING !!
0 · Reply
tylergrant
tylergrant Nov. 17 at 2:16 AM
I got stopped out of $TNXP at $17 earlier. I'll be looking for an entry but this has no support on the chart. Combine that with an unloved name means we might get a single digit opportunity. Biotechs are in a "prove it" mood so the next 2 quarters, if successful, will be rerated
0 · Reply
Hoppanin
Hoppanin Nov. 17 at 2:10 AM
$TNXP TONMYA SAVINGS PROGRAM!!!
3 · Reply
TrendSetter67
TrendSetter67 Nov. 17 at 1:56 AM
$TNXP ...chicken dinner
1 · Reply
JRoc16
JRoc16 Nov. 17 at 1:47 AM
$TNXP Catch ya at the 130...!
0 · Reply
melissascrookedtooth
melissascrookedtooth Nov. 17 at 1:18 AM
$TNXP don't know if these were live previously https://www.tonmya.com/sign-up https://www.tonmya.com/savings
1 · Reply
Latest News on TNXP
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook

Nov 14, 2025, 9:41 AM EST - 2 days ago

Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 10, 2025, 4:15 PM EST - 6 days ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 6, 2025, 7:00 AM EST - 10 days ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Nov 4, 2025, 7:00 AM EST - 12 days ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 28, 2025, 7:00 AM EDT - 19 days ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 27, 2025, 7:00 AM EDT - 20 days ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 22, 2025, 7:00 AM EDT - 25 days ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 21, 2025, 7:00 AM EDT - 26 days ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 17, 2025, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Oct 9, 2025, 7:00 AM EDT - 5 weeks ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 30, 2025, 8:30 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 29, 2025, 7:00 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 18, 2025, 8:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 17, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Sep 8, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

Aug 19, 2025, 12:28 PM EDT - 3 months ago

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

Tonix Secures Fibromyalgia Approval - What Investors Should Know

Aug 16, 2025, 8:45 AM EDT - 3 months ago

Tonix Secures Fibromyalgia Approval - What Investors Should Know

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:50 PM EDT - 3 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 15, 2025, 3:44 PM EDT - 3 months ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 11, 2025, 4:15 PM EDT - 3 months ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 21, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 10, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 9, 2025, 4:01 PM EDT - 4 months ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 7, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jul 2, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Jun 16, 2025, 11:30 AM EDT - 5 months ago

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 16, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Jun 13, 2025, 7:30 AM EDT - 5 months ago

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Jun 13, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Jun 10, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 5, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

May 22, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 21, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

May 14, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

May 12, 2025, 4:30 PM EDT - 6 months ago

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Apr 29, 2025, 9:05 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 24, 2025, 7:55 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Apr 16, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Apr 9, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Apr 7, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Mar 27, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Mar 26, 2025, 2:30 AM EDT - 8 months ago

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Mar 25, 2025, 8:16 AM EDT - 8 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

ARQT

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Mar 24, 2025, 8:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

ThatDudeWithNoMoney
ThatDudeWithNoMoney Nov. 17 at 4:25 AM
$TNXP To all my OG Tonix investors from 2019-2022 era. Idk if y'all are still here or lurking but it's fucking insane to have gone through all of those reverse splits and lost money to finally see TNX-102SL (Tonmya) finally hit the market. I, for one, made my losses back and made a nice profit when they announced the PDUFA news almost a year ago. Anyway, I'll be buying back in 3 months once their earnings come around. You newer investors have a nicer setup than what we had haha
1 · Reply
YourAverageStockGuy
YourAverageStockGuy Nov. 17 at 3:59 AM
$TNXP
0 · Reply
TrendSetter67
TrendSetter67 Nov. 17 at 3:06 AM
$TNXP Hey Now... the AI is channeling thoughts of a Squeeze
0 · Reply
TrendSetter67
TrendSetter67 Nov. 17 at 2:54 AM
$TNXP How did it get to #5 so quickly this evening? Driven by views rather than posts?
1 · Reply
JRoc16
JRoc16 Nov. 17 at 2:51 AM
$TNXP Tonmya Hits The Market !! Lets Freaking Go !! TRENDING !!
0 · Reply
tylergrant
tylergrant Nov. 17 at 2:16 AM
I got stopped out of $TNXP at $17 earlier. I'll be looking for an entry but this has no support on the chart. Combine that with an unloved name means we might get a single digit opportunity. Biotechs are in a "prove it" mood so the next 2 quarters, if successful, will be rerated
0 · Reply
Hoppanin
Hoppanin Nov. 17 at 2:10 AM
$TNXP TONMYA SAVINGS PROGRAM!!!
3 · Reply
TrendSetter67
TrendSetter67 Nov. 17 at 1:56 AM
$TNXP ...chicken dinner
1 · Reply
JRoc16
JRoc16 Nov. 17 at 1:47 AM
$TNXP Catch ya at the 130...!
0 · Reply
melissascrookedtooth
melissascrookedtooth Nov. 17 at 1:18 AM
$TNXP don't know if these were live previously https://www.tonmya.com/sign-up https://www.tonmya.com/savings
1 · Reply
alphonns
alphonns Nov. 17 at 1:09 AM
$TNXP https://www.marketbeat.com/instant-alerts/tonix-pharmaceuticals-nasdaqtnxp-raised-to-hold-at-wall-street-zen-2025-11-15/
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 9:58 PM
Hedge Alert Live - Protect Your Portfolio Contract: $TNXP $15.00 Put · NOV 21, 2025 Exp Entry Price: $1.25 - $2.25 Exit Price Target: $2.95 Profit Margin: +136% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
JustAguysOpinion
JustAguysOpinion Nov. 16 at 8:34 PM
$TNXP This ticker 10x twice in less than 12 months. Went from .14 to over 1.60 in 1 day in December. Then from 7 to 70. Market not a place for emotions
1 · Reply
Karanjot
Karanjot Nov. 16 at 6:24 PM
$TNXP this fucker comments on my post and blocked me and ran away like a chicken , one word for him suck my d**k 🖕🖕i been investing in this shitty company from last 5 years go back and check there history how many reverse split they have done , If u have invested 80k in this stick from last 5 years today your current portfolio value will be $1 , So whenever u want to open your mouth next time just suck my d**k and keep quiet
1 · Reply
Manu56
Manu56 Nov. 16 at 5:48 PM
$TNXP Karen-jot 🤣🤣🤣 Blocked and in the bin, bye-bye 👋 fool 😎
1 · Reply
Luka_Brasi
Luka_Brasi Nov. 16 at 4:45 PM
$TNXP Holding up pretty well today. Mr Lederman likes to dilute after hours Fridays.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 16 at 6:46 AM
Enter: $TNXP Calls Strike Price: $18 Expiry Date: DEC 19 2025 Buy in Price: $2.30 - $3.90 Sell Price: $4.90 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Nov. 16 at 1:40 AM
$TNXP balance sheet is too good for this to not spring back up to 50-70 range once scripts start floating.
1 · Reply
Vidan48
Vidan48 Nov. 16 at 1:08 AM
$TNXP Not! You couldn’t take it to $1 before FDA approval. Definitely not happening after approval. These are the ignorant, useless comments that shorties post. Whomever falls for this should pass go and go straight to the casinos. No substance just pure ignorance. These handles are an easy block! GL
0 · Reply
Karanjot
Karanjot Nov. 16 at 1:03 AM
$TNXP believe it or not , this shit is going back to $1 to its comfort zone
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:00 PM
Hedge Alert Live - Protect Your Portfolio Contract: $TNXP $15.00 Put · NOV 21, 2025 Exp Entry Price: $1.25 - $2.25 Exit Price Target: $2.95 Profit Margin: +136% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Vidan48
Vidan48 Nov. 15 at 5:15 PM
$TNXP There are many strong bulls on this board but @carronsbfc is the lead that you should carefully listen to. He understands the meaning of being an investor and is level headed with his assessments. Facts and logic help pull you through at times where doubt runs deep. Companies number one priority is growth. Without this success isn’t viable. It’s taken this company many years to finally achieve FDA approval. Now supply and demand will dictate its future. Looking at charts and performing technical analysis means nothing today. No one has ever predicted the perfect entry price correctly. The question is whether you believe that the SP is undervalued or overvalued. Living in the past will cloud your judgement and fear will hamper your ability to make rational decisions. Causing stagnation in achieving financial independence. It’s not always easy to be an investor. It’s boring but patience is a strength most won’t ever achieve. GL Everyone!
2 · Reply